{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Status:
Investigational
Source:
NCT00839631: Phase 1 Interventional Completed Solid Tumors
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02253342: Phase 1 Interventional Completed Intrapulmonary Pharmacokinetics of WCK 2349
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Levonadifloxacin is the S-(-) isomer of the benzoquinolizine fluoroquinolone nadifloxacin and is two- to four-fold more active than the racemic mixture. Levonadifloxacin is a potent antibacterial agent against Gram-positive bacteria especially against methicillin resistance Staphylococcus aureus. It also possesses potent bactericidal activity against other resistant variants like quinolone-resistant Staphylococcus aureus, vancomycin and glycopeptide intermediate Staphylococcus aureus and vancomycin resistant Staphylococcus aureus. Intravenous dosage form developed to treat complicated skin and skin structure infections and has recently completed Phase III studies in India and Phase I studies in USA.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Piflutixol is a thioxanthene neuroleptic which combines a very potent dopamine antagonistic effect with a potent effect in tests for sedative properties. It was found to have a very strong antagonistic effect against stereotypies induced by dopamine agonists in mice, rats and dogs as well as against apomorphine induced vomiting in dogs. This indicates that piflutixol must be considered as one of the most potent dopamine receptor blocking agents. Piflutixol seems to be the hitherto most potent inhibitor of dopamine-stimulated adenylate cyclase. There was a linear relationship between D-1 dopamine receptor occupation by [3H]piflutixol and inhibition of dopamine sensitive adenylate cyclase. Piflutixol markedly antagonizes the effect of noradrenaline, 5-HT and to some extent histamine, whereas the affinity for muscarinic receptors was rather weak. Piflutixol has a high affinity for dopamine structures within the brain. It is a compound with a very long duration of action.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Guamecycline, a tetracycline derivative was studied in patients with broncho-pulmonary diseases and for the treatment of acute pneumopathies. However, information about the current use of this compound is not available.
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
Pranolium (UM-272) is propranolol derivative. It can reduce the extent of myocardial injury sustained during severe ischemia. UM-272 lacks significant beta-adrenergic blocking activity but retains the negative chronotropic, negative inotropic and antiarrhythmic effects common to both d- and l-propranolol. The protective effects of UM-272 during myocardial ischemia cannot be due to metabolic effects of the beta-adrenergic blockade but may be due to effects on oxygen consumption or to effects on myocardial membrane properties that are related to its antiarrhythmic and myocardial depressant activity. The ability of UM-272 to enhance blood flow to subendocardial myocardium may also play a role in its beneficial effects during ischemia. UM-272 may protect the ischemic heart through direct effects on myocardial Ca++ regulating mechanisms. UM-272 has kinetically similar use-dependent inhibitory action of the fast sodium channels of cardiac muscles as other Class Ia antiarrhythmic drugs like quinidine or procainamide. Pranolium was investigated as an antiarrhythmic agent.
Status:
Investigational
Source:
INN:flerobuterol [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
FLEROBUTEROL is a beta-adrenoceptor agonist with potential antidepressant activity.
Status:
Investigational
Source:
NCT02342691: Phase 1/Phase 2 Interventional Completed Gingival Inflammation
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Benzo-lipoxin A4 as a bLXA4-ME also known as ClinRinse-1 participated in phase II clinical trials for the treatment of gingival diseases. It was shown that nano-proresolving medicines (NPRM) containing a lipoxin analog (benzo-lipoxin A4, bLXA4) was a mimetic of endogenous resolving mechanisms with potent bioactions. That offered a new therapeutic tissue-engineering approach for the treatment of chronic osteolytic inflammatory diseases.
Class (Stereo):
CHEMICAL (RACEMIC)
Amfepentorex (CB 2201) was marketed as an appetite suppressant in France in the 1970s.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Normorphine is an opiate analog, specifically the N-demethylated derivative of morphine. It was first described in the 1953 as part of an effort to characterize N-substituted morphine analogs. Normorphine has relatively little opioid activity, but it is a useful intermediate for the production of more potent morphine analogs. It is also a major metabolite of morphine.
Status:
Investigational
Source:
NCT04035473: Phase 1 Interventional Completed Solid Tumor
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
HM-30181 is a highly selective and potent inhibitor of Multi-drug resistance 1 (MDR1, ABCB1), also known as P-glycoprotein (P-gp). Co-administration of HM30181 greatly increased oral bioavailability of tubulin-stabilizing chemotherapeutic agent paclitaxel. Oraxol is an oral dosage form of paclitaxel administered orally with the HM30181A molecule. Oraxol offers patients with paclitaxel-responsive tumors the possibility of oral therapy without the requirement for premedication to prevent infusion-related hypersensitivity-type reactions. Current clinical data suggests the promising potential of a better clinical response and tolerability profile, which can likely to be attributed to the better pharmacokinetic profile achieved. Oraxol is presently in a Phase 3 trial in metastatic breast cancer and poised to enter into a combination study for treatment of advanced gastric cancer with ramucirumab through a clinical trial collaboration with Eli Lilly and Company.
